Myelodysplastic syndromes: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

EU-13 is a filter, not a ranking: it only narrows the list.

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Updated 20 Oct 2026

  “The trial closed early due to changes in support for the study drug.”Registry text, quoted unchanged. Source

• Terminated

  A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Novartis Pharmaceuticals· Updated 13 Jan 2026

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Updated 13 Jan 2026

  “In December 2023, Novartis decided to terminate the sabatolimab clinical development program early after Phase II (MDS1) and Phase III (MDS2) studies failed to meet their primary objectives. The termination was not due to safety concerns.”Registry text, quoted unchanged. Source

• Terminated

  STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Novartis Pharmaceuticals· Updated 16 Oct 2025

  “Lack of efficacy in the program as demonstrated in the earlier CMBG453B12301 (STIMULUS MDS-2) study.”Registry text, quoted unchanged. Source

• Terminated

  HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)

  NCT03940352· Novartis Pharmaceuticals· Updated 10 Oct 2025

  “Business decision”Registry text, quoted unchanged. Source

• Withdrawn

  A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

  NCT05367401· Novartis Pharmaceuticals· Updated 11 Apr 2024

  “waiting for update from Study Lead”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• MBG453 in Lower Risk MDS

  NCT04823624· Massachusetts General Hospital· Source

• A Study of MBG453 in Combination With Hypomethylating Agents in Subjects With IPSS-R Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS).

  NCT03946670· Novartis Pharmaceuticals· Source

• Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  NCT04266301· Novartis Pharmaceuticals· Source

• STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS

  NCT04878432· Novartis Pharmaceuticals· Source

• A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

  NCT05367401· Novartis Pharmaceuticals· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• The role of computational pathology in predicting expression of selected immunohistochemical markers.

  Pol J Pathol, Jun 2026

• An open bone marrow megakaryocyte dataset for automated morphologic studies.

  Sci Data, Dec 2025

• Deep learning in bone marrow cytomorphology: advances in segmentation, classification, and clinical translation.

  Med Oncol, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.